CancerDrs

Prostate Cancer clinical trials in Alabama

7 actively recruiting prostate cancer trials at 5 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • The Kirklin Clinic at Acton Road — Birmingham, Alabama
  • Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Alabama:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07190300
Sites in Alabama:
  • Univ of Alabama at Birmingham — Birmingham, Alabama
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Alabama:
  • University of Alabama at Birmingham Hospital — Birmingham, Alabama
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Alabama:
  • Massive Bio SYNERGY-AI site — Birmingham, Alabama
  • Massive Bio SYNERGY-AI site — Mobile, Alabama
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17